On June 7, 2020, Sanuwave Health, Inc. (the “Company”) entered into an agreement with Celularity Inc. (“Celularity”) to which the Company paid Celularity $1,110,000 for an exclusive and irrevocable option to purchase Celularity’s UltraMIST assets and partnership rights for its wound care biologic products. The payment for the option is non-refundable, but upon the consummation of the acquisition of such assets and rights on substantially the terms set forth in the non-binding letter of intent previously executed by the parties, such option payment shall be deducted from the purchase price. The option automatically expires on July 14, 2020.
The Company issued a press release regarding the option agreement entered into with Celularity. A copy of the press release is furnished as Exhibit 99.1 hereto.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
99.1
Press Release issued by the Company on June 10, 2020
SANUWAVE Health, Inc. ExhibitEX-99.1 2 snwv_ex991.htm PRESS RELEASE snwv_ex991 Exhibit 99.1 SANUWAVE HEALTH ENTERS INTO EXCLUSIVE LETTER OF INTENT TO ACQUIRE CELULARITY’S ULTRAMIST® AND EXCLUSIVE PARTNERSHIP RIGHTS FOR WOUND CARE BIOLOGIC PRODUCTS Contemplated Transaction Would Create a Leading Provider of Advanced Wound Care Solutions that Improve Clinical Outcomes Across the Continuum of Care SUWANEE,…
To view the full exhibit click
here
About SANUWAVE Health, Inc. (OTCMKTS:SNWV)
SANUWAVE Health, Inc. is an acoustic pressure shock wave technology company using a system of noninvasive, high-energy, acoustic pressure shock waves for indications, such as regenerative medicine and other applications. The Company is focused on regenerative medicine utilizing noninvasive (extracorporeal), acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, enabling to restore the body’s normal healing processes and regeneration. It is focused on developing its Pulsed Acoustic Cellular Expression (PACE) technology to activate healing in wound conditions.
